Tiziana to begin testing foralumab in multiple system atrophy
Source: SeekingAlpha
2025-08-11 09:29:05 ET
More on Tiziana Life Sciences
- Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting
- Seeking Alpha’s Quant Rating on Tiziana Life Sciences
- Historical earnings data for Tiziana Life Sciences
- Financial information for Tiziana Life Sciences
Read the full article on Seeking Alpha
For further details see:
Tiziana to begin testing foralumab in multiple system atrophy
Tiziana Life Sciences plc
NASDAQ: TLSA
TLSA Trading
-4.69% G/L:
$1.22 Last:
67,692 Volume:
$1.27 Open:
TLSA Latest News
February 25, 2026 07:00:00 am
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
January 20, 2026 11:15:00 am
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
January 16, 2026 02:45:30 pm
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
January 16, 2026 07:00:00 am
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
TLSA Stock Data
$181,980,557
76,474,803
70.7%
10
N/A
Biotechnology & Life Sciences
Healthcare
BM
London
